U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. CardioGen-82 Information
  1. Postmarket Drug Safety Information for Patients and Providers

CardioGen-82 Information

CardioGen-82 is a radionuclide generator that produces Rb-82 chloride injection; the Rb-82 emits the radiation detected in a PET scan.

Rb-82 is a medical isotope with a short half-life (75 seconds), and is derived from strontium-82 (Sr-82), which has a half-life of 25 days.
Rb-82 is collected from the generator column by injecting a solution of normal saline through the column. Under normal conditions, only the Rb-82 is released into the solution, while the strontium remains attached to the column.

 


To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this apge.

 

Related Information

Labeling and Regulatory History from Drugs@FDA

Back to Top